[Antibiotic combinations in Staphylococcus aureus infections: arguments in favour].
More than 40% of Staphylococcus aureus strains isolated in hospitals are methicillin-resistant, thus posing daily problems regarding therapy. The treatment of these infections is principally based on glycopeptides. The need or not to combine them, first-line or second-line, with another antibiotic, remains a subject for debate. In this article, we have endeavoured to demonstrate the validity of arguments which plead in favour of using glycopeptides in combination, and not as single-drug therapy.
Potel
G
G
Laboratoire d'antibiologie expérimentale et clinique, UPRES EA 1156, faculté de médecine, 1, rue Gaston-Veil, 44000 Nantes, France. gpotel@sante.univ-nantes.fr
D000900:Anti-Bacterial Agents; D000075202:Contraindications; D004351:Drug Resistance / Q000235:genetics; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics
D000900:Anti-Bacterial Agents